TAAR1 and obesity disorder: The key findings of the present study are as follows: (i) 4-OH-Guanabenz causes a significant decrease in body weight of animals with developed obesity, (ii) a significant decrease in blood glucose and triglycerides levels, (iii) it is a partial agonist of the α2A-adrenoceptor and may act at TAAR1, (iv) it does not significantly affect body core temperature, (v) it does not significantly affect locomotor activity, and (vi) its effect on blood pressure does not appear to be significant.